Confident glycan characterization with EAD‑enabled LC‑MS workflows by Roxana McCloskey | Jun 30, 2026 | Biopharma, BlogsGlycosylation is one of the more structurally diverse and biologically impactful PTMs in protein therapeutics. Both N‑linked and O‑linked glycans influence protein folding, stability, and biological activity. Given these effects on biotherapeutics, glycosylation is a closely monitored critical quality attribute (CQA). Comprehensive and site‑specific characterization of glycosylation is essential for informed decision‑making throughout drug discovery and development.
7 risks every lab should consider before the warranty ends by Andrea Mueller | Jun 24, 2026 | Blogs, Service, Support, TechnologyWarranty expiration is more than an administrative milestone—it is a transition point that can significantly impact instrument uptime, laboratory productivity, operating budgets, and scientific outcomes.
Accelerating Echo® MS system optimization with LeadScape® by Kean Woodmansey | Jun 17, 2026 | Blogs, Echo® MS+ system, Pharma, SCIEX OS softwareFor more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.
PFAS explained: What they are, why they matter, and what’s changing by Simon Roberts | Jun 17, 2026 | Blogs, Environmental / Industrial, Food / BeveragePFAS are increasingly at the center of regulatory change, scientific research, and industry discussion worldwide. As analytical capabilities improve and expectations around environmental responsibility continue to evolve, understanding the role PFAS play, and how they are being addressed, has never been more important. This blog provides an overview of what PFAS are, why they matter, and how responses from regulators and industry are changing.
Pesticide residue testing in food: Supporting confident and compliant analysis by SCIEX Community | Jun 11, 2026 | Blogs, Food / BeveragePesticides are widely used in agriculture to protect crops and maintain yield, but their presence in food must be carefully monitored. To safeguard consumers, regulatory authorities worldwide set maximum residue limits (MRLs), often at very low concentrations and across a wide range of compound classes.
Why capillary electrophoresis still matters in modern biopharma by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CEExplore why capillary electrophoresis remains essential for high resolution, confident analytics across modern biopharma modalities, from proteins to mRNA and gene therapies
Where does capillary electrophoresis fit across drug development? by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CECapillary electrophoresis (CE) is not confined to a single point in the drug development lifecycle. Its value comes from the ability to deliver high‑resolution, reproducible separations that remain relevant as analytical questions evolve, from early discovery through late‑stage development and lot release.
Introducing the SCIEX resource hub: All your resources, one place by Susanna Baqué | May 27, 2026 | Blogs, Support, Technology, TrainingFinding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
Why middle‑down and subunit MS analyses powered by EAD are transforming biopharmaceutical characterization by Roxana McCloskey | May 15, 2026 | Biopharma, BlogsAs an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows by Roxana McCloskey | Apr 29, 2026 | Biopharma, BlogsIn biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.